Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
- Sponsor
- Beni-Suef University
- Study ID
- NCT07323329
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Infertility
- Infertility (IVF Patients)
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 35 Years
- Healthy Volunteers
- Not accepted
Interventions
- Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day. — DRUGPatients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
- DHEA plus folic acid 400mcg per day — DRUGPatients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
- control group — DIETARY_SUPPLEMENTPatients will receive folic acid 400 mcg per day
Study Details
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Key Dates
- First listed
- Jan 7, 2026
- Start date
- Oct 10, 2025
- Status verified
- Dec 2025
- Primary completion
- Oct 15, 2026
- Completion
- Nov 12, 2026
Study Design
- Enrollment
- 165 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Somatropin groupSomatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day
- Experimental: dehydroepiandrosteronedehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
- Active Comparator: Standard carePatients will receive standard care will receive folic acid 400 mcg per day
Primary Outcome Measure
The number of mature oocyte [ Time Frame: 12 weeks ]
Related Studies
- Study to Create Potential Cell-Based Therapies to Treat Human Disease and DisabilityEnrolling By Invitation · Stanford University · Stanford, California
- Discarded Materials StudyRecruiting · Reproductive Medicine Associates of New Jersey · Basking Ridge, New Jersey
- Study of Gene Associations and InfertilityEnrolling By Invitation · Reproductive Medicine Associates of New Jersey · Basking Ridge, New Jersey
- Inherited Reproductive DisordersRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Bethesda, Maryland